GALT250117P4000
- 2.81
- 0.000.00%
Galectin Therapeutics Newsroom
Galectin Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Galectin Therapeutics Analyst Ratings
H.C. Wainwright Downgrades Galectin Therapeutics(GALT.US) to Hold Rating
H.C. Wainwright Downgrades Galectin Therapeutics After MASH Trial Fails
Insider Purchase: Director at $GALT (GALT) Buys 13,469 Shares
12 Health Care Stocks Moving In Friday's Pre-Market Session
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint
Top Midday Decliners
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Dow Surges 100 Points, Carnival Earnings Top Views
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
Galectin's Belapectin Study Shows Mixed Endpoint Results; Shares Fall Pre-Bell
Galectin Drops as Trial for Lead Asset Fails in MASH
Galectin Therapeutics Shares Are Trading Lower After the Company Announced Top-line Results of Its NAVIGATE Clinical Trial and Confirmed Belapectin Did Not Achieve Statistical Significance.
Express News | Galectin Therapeutics Shares Fall 50% Premarket After Liver Disease Drug Fails to Meet Main Goal in Study
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients With Cirrhotic Portal Hypertension Caused by MASH
Express News | Galectin Therapeutics Inc - Belapectin Shows Significant Reduction in Esophageal Varices in 2Mg/Kg Cohort
Express News | Galectin Therapeutics Inc - Belapectin Did Not Achieve Statistical Significance in Intent-to-Treat Population
Express News | Galectin Therapeutics Inc - Belapectin Well Tolerated With No Safety Signals